0001829126-26-004854
SEC filingRevenue declined 63.5% year-over-year to $14.9K, driven by the absence of a large international equipment sale from Q1 FY2025 — highlighting Nexalin’s reliance on non-recurring device transactions amid a transitional commercial model.
Revenue for Q1 FY2026 was $14.9K, down 63.5% from $41.0K in Q1 FY2025. As disclosed in Management’s Discussion, this decline was primarily due to lower equipment sales to an international customer during the current period — not broad-based demand weakness or operational deterioration. This underscores Nexalin’s current revenue model: minimal recurring domestic licensing and electrode sales, paused U.S. marketing of new devices following FDA reclassification, and infrequent international Gen-2 equipment shipments. The resulting top line is inherently lumpy and unsustainable without regulatory clearance for next-generation platforms.
Gross profit declined 52.2% YoY to $13.1K, yet gross margin improved to 87.8%. This divergence reflects a compositional shift — not improved cost control or scale. With equipment sales (lower-margin, higher-volume) absent this quarter, the remaining revenue consisted disproportionately of higher-margin licensing fees and consumables. Management does not attribute this margin improvement to operational leverage; rather, it arises from the relative absence of hardware transactions, which carry lower margins and higher fulfillment costs.
Net cash used in operating activities was -$1.7M, up from -$1.4M in Q1 FY2025. Management attributes the change in current liabilities — particularly a decrease in accounts payable — to the timing of vendor payments. This working capital volatility, not a fundamental shift in underlying burn rate, explains why operating cash outflow exceeded net loss. Future fluctuations are expected to continue being driven by timing of expenditures, vendor payments, and capital raising activities, including potential use of the ATM program.
Management explicitly states that additional capital will be required to fund planned clinical and operating activities — including the pivotal insomnia study — beyond current cash resources. Primary uses of capital include compensation, third-party clinical R&D services, manufacturing development, legal and regulatory expenses, and general administrative costs. The Company anticipates continued operating losses through 2026 and beyond, with no assurance that development initiatives will yield benefits within expected timeframes.